WAVE Life Sciences Ltd
NASDAQ:WVE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.48
21.31
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
WAVE Life Sciences Ltd
Revenue
WAVE Life Sciences Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
WAVE Life Sciences Ltd
NASDAQ:WVE
|
Revenue
$109.2m
|
CAGR 3-Years
197%
|
CAGR 5-Years
53%
|
CAGR 10-Years
92%
|
|
|
Haw Par Corporation Ltd
SGX:H02
|
Revenue
S$253m
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
H
|
Hyphens Pharma International Ltd
SGX:1J5
|
Revenue
S$185.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
I
|
IX Biopharma Ltd
SGX:42C
|
Revenue
S$7.8m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
WAVE Life Sciences Ltd
Glance View
WAVE Life Sciences Ltd. is a biotechnology company that sprawls across the intricate landscape of genetic medicine, focusing tirelessly on harnessing the therapeutic potential of stereochemistry in designing drugs. Founded with an innovative spirit, the company has carved out a niche by developing stereopure oligonucleotides, which are synthetically crafted RNA or DNA molecules tailored to enhance therapeutic efficacy and safety. The precision and clarity with which WAVE defines each aspect of its drug candidates separate them from many competitors in the gene therapy arena. With their proprietary platform, PRISM, WAVE leverages a deep understanding of genetic and molecular nuances to address rare genetic diseases. Their pipeline is reflective of this targeted approach, with clinical trials and research focusing on conditions like Huntington's disease, Duchenne Muscular Dystrophy, and other inherited disorders that have limited treatment options. The business model of WAVE revolves around both in-house development and strategic partnerships, driving revenue through research collaborations and potential milestone payments. By collaborating with larger pharmaceutical entities, WAVE amplifies its reach and resources, allowing it to tackle more complex challenges in genetic diseases. These partnerships are financially synergistic, enabling WAVE to continuously invest in its R&D efforts, which are pivotal for long-term growth and sustainability. The company’s focus on innovative medicines and the establishment of credible partnerships underscores its dual strategy of creating breakthrough treatments while maintaining a robust financial backbone, striving to transform the landscape of genetic therapies ethically and effectively.
See Also
What is WAVE Life Sciences Ltd's Revenue?
Revenue
109.2m
USD
Based on the financial report for Sep 30, 2025, WAVE Life Sciences Ltd's Revenue amounts to 109.2m USD.
What is WAVE Life Sciences Ltd's Revenue growth rate?
Revenue CAGR 10Y
92%
Over the last year, the Revenue growth was 104%. The average annual Revenue growth rates for WAVE Life Sciences Ltd have been 197% over the past three years , 53% over the past five years , and 92% over the past ten years .